Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys

被引:23
作者
Cornelissen, Jeremy C. [1 ]
Obeng, Samuel [2 ]
Rice, Kenner C. [3 ,4 ]
Zhang, Yan [2 ]
Negus, S. Stevens [1 ]
Banks, Matthew L. [1 ]
机构
[1] Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, 410 North 12th St,Box 980613, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, Richmond, VA USA
[3] NIDA, Drug Design & Synth Sect, Mol Targets & Medicat Discovery Branch, Bethesda, MD 20892 USA
[4] NIAAA, Bethesda, MD USA
基金
美国国家卫生研究院;
关键词
APPARENT PA(2) ANALYSIS; IN-VIVO; DISCRIMINATIVE STIMULUS; ANTINOCICEPTIVE INTERACTIONS; MEDIATED ANTINOCICEPTION; BETA-FUNALTREXAMINE; THERMAL NOCICEPTION; SQUIRREL-MONKEYS; EFFICACY; BUPRENORPHINE;
D O I
10.1124/jpet.117.246439
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Receptor theory predicts that fixed-proportion mixtures of a competitive, reversible agonist (e.g., fentanyl) and antagonist (e.g., naltrexone) at a common receptor [e.g., mu-opioid receptors (MORs)] will result in antagonist proportion-dependent decreases in apparent efficacy of the agonist/antagonist mixtures and downward shifts in mixture dose-effect functions. The present study tested this hypothesis by evaluating behavioral effects of fixed-proportion fentanyl/naltrexone mixtures in a warm-water tail-withdrawal procedure in rhesus monkeys (n = 4). Fentanyl (0.001-0.056 mg/kg) alone, naltrexone (0.032-1.0 mg/kg, i.m.) alone, and fixed-proportion mixtures of fentanyl/naltrexone (1: 0.025, 1: 0.074, and 1: 0.22) were administered in a cumulative-dosing procedure, and the proportions were based on published fentanyl and naltrexone K-d values at MOR in monkey brain. Fentanyl alone produced dose-dependent antinociception at both 50 and 54 degrees C thermal intensities. Up to the largest dose tested, naltrexone alone did not alter nociception. Consistent with receptor theory predictions, naltrexone produced a proportion-dependent decrease in the effectiveness of fentanyl/naltrexone mixtures to produce antinociception. The maximum effects of fentanyl, naltrexone, and each mixture were also used to generate an efficacy-effect scale for antinociception at each temperature, and this scale was evaluated for its utility in quantifying 1) efficacy requirements for antinociception at 50 and 54 degrees C and 2) relative efficacy of six MOR agonists that vary in their efficacies to produce agonist-stimuated GTP gamma S binding in vitro (from lowest to highest efficacy: 17-cyclopropylmethyl-3,14 beta-dihyroxy-4,5 alpha-epoxy-6 alpha[(3'-isoquinolyl)acetamindo] morphine, nalbuphine, buprenorphine, oxycodone, morphine, and methadone). These results suggest that fixed-proportion agonist/antagonist mixtures may offer a useful strategy to manipulate apparent drug efficacy for basic research or therapeutic purposes.
引用
收藏
页码:37 / 47
页数:11
相关论文
共 50 条
[1]  
Alt A, 2001, J PHARMACOL EXP THER, V298, P116
[2]   Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics [J].
Banks, Matthew L. ;
Folk, John E. ;
Rice, Kenner C. ;
Negus, S. Stevens .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2010, 97 (02) :205-212
[3]   Antinociceptive Interactions between Mu-Opioid Receptor Agonists and the Serotonin Uptake Inhibitor Clomipramine in Rhesus Monkeys: Role of Mu Agonist Efficacy [J].
Banks, Matthew L. ;
Rice, Kenner C. ;
Negus, S. Stevens .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (02) :497-505
[4]   Agonist efficacy, drug dependence, and medications development:: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands [J].
Bergman, J ;
France, CP ;
Holtzman, SG ;
Katz, JL ;
Koek, W ;
Stephens, DN .
PSYCHOPHARMACOLOGY, 2000, 153 (01) :67-84
[5]   Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys [J].
Bowen, CA ;
Fischer, BD ;
Mello, NK ;
Negus, SS .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :264-273
[6]   Buprenorphine-Naloxone Therapy in Pain Management [J].
Chen, Kelly Yan ;
Chen, Lucy ;
Mao, Jianren .
ANESTHESIOLOGY, 2014, 120 (05) :1262-1274
[7]   A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates [J].
Ding, Huiping ;
Czoty, Paul W. ;
Kiguchi, Norikazu ;
Cami-Kobeci, Gerta ;
Sukhtankar, Devki D. ;
Nader, Michael A. ;
Husbands, Stephen M. ;
Ko, Mei-Chuan .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (37) :E5511-E5518
[8]  
EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630
[9]  
Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121
[10]   Developments in managing severe chronic pain: role of oxycodone-naloxone extended release [J].
Fanelli, Guido ;
Fanelli, Andrea .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :3811-3816